Floatz logo

Bcma Targeted Car T-Cells

Autoimmune Encephalitis (AE)

Tongji HospitalCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Autoimmune Encephalitis (AE) cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Tongji Hospital
Phase 2BB
HUMAN IMMUNOGLOBULINS
University of Utah
Phase 2CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Cambridge
Phase 2CCC
IMMUNOGLOBULIN G2, ANTI-(HUMAN CD19 (ANTIGEN)) (SYNTHETIC HUMAN MONOCLONAL MEDI-551 HEAVY CHAIN), DISULFIDE WITH SYNTHETIC HUMAN MONOCLONAL MEDI-551 .KAPPA.-CHAIN, DIMER
University of Utah
Phase 2CCC
Fludarabine
Tongji Hospital
Phase 1CCC

View all 9 →

Same molecule, other indications

Bcma Targeted Car T-Cells is also rated in:

myasthenia gravisDormant
C
Indicative ·
39 / 100
View asset →
multiple sclerosisDormant
C
Indicative ·
39 / 100
View asset →
chronic inflammatory demyelinating polyradiculoneuropathyDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →